Stockreport

Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting

Innate Pharma S.A. - American Depositary Shares  (IPHA) 
PDF IPH4502 is a novel and differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors.IPH4502 demonstrated p [Read more]